tbuckley/cabot-search huggingface dataset:
Pilot project: preventing further AIDS spread among women, general heterosexual population
Authors: C. A. Raymond
Journal: JAMA (1988)

BY 1991, according to some projections, women will account for 12% of cases of acquired immunodeficiency syndrome (AIDS). Public health experts are hoping to intervene now to prevent further spread of AIDS among women and into the heterosexual population in general. Three cities are embarking on an innovative pilot education and prevention program to reach "a diverse and scattered group, many of whom do not know they are at increased risk," said Sheila Namir, PhD, at the Boston meeting of the Society of Behavioral Medicine. Namir is assistant professor at the California College of Professional Psychology in Los Angeles. The Women and AIDS Risk Network (WARN), which Namir heads, is putting the finishing touches on a program that will begin in Boston, Phoenix, and Los Angeles. The program will target sexual partners of intravenous drug users and users themselves, prostitutes, prisoners, adolescent runaways, and the homeless. It is being funded
The severity of liver disease influences HCV replication in patients with chronic hepatitis C . 1Liver Transplant Unit and 2Department of Virology, H�pital Henri Mondor, Universit� Paris XII, Cr�til, France
Journal: Hepatology (1995)

Using a commercial source of peroxidase-labelled anti-C3d antibody (Dakopatts), an enzyme-linked immunosorbent assay (ELISA) has been developed to quantify the complement fragment C3d. The technique enables the detection of C3d in plasma, urine and cerebrospinal fluid (CSF). The C3d-ELISA therefore provides a very sensitive technique for the evaluation of complement activation in biological fluids. In both plasma and urine the technique is able to discriminate between samples from normal controls and patients with rheumatoid arthritis in whom complement activation is known to occur. A good correlation was found between results obtained by ELISA and those by laser nephelometry (r = 0.91, P < 0.0001). Microtitre plates pre-coated with anti-C3d antibody and subsequently stored at −70°C retained the ability to perform in this assay. The sensitivity, short assay time and use of commercial reagents and pre-coated plates give this technique numerous potential applications in the evaluation of complement activation.
INFANTILE CONVULSIONS....
Authors: I. N. LOVE
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
L'année obstétricale. (Travaux de 1925).
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
EMBR-16. SMOOTHENED-ACTIVATING LIPIDS DRIVE RESISTANCE TO CDK4/6 INHIBITION IN HEDGEHOG-ASSOCIATED MEDULLOBLASTOMA
Authors: Vikas Daggubati, Jordan Hochstelter, Anirudh Bommireddy, Abrar Choudhury, Alexis Leigh Krup, Pervinder Choski, Pakteema Tong, Amy Li, Libin Xu, Jeremy Reiter, David Raleigh
Journal: Neuro-Oncology (2021)

Abstract Background Medulloblastoma is an aggressive pediatric brain tumor that is associated with misactivation of the Hedgehog (HH) pathway. Our lab has shown that CDK6, a critical activator of the cell cycle, is a direct transcriptional target of oncogenic HH signaling, and that inhibiting CDK6 blocks the growth of HH-associated medulloblastoma in mice. A clinical trial exploring the efficacy of CDK6 inhibition in medulloblastoma patients is underway, but prior attempts to target the HH pathway in medulloblastoma have been encumbered by resistance to molecular monotherapy. Thus, we sought to identify mechanisms of resistance to CDK6 inhibition in HH-associated medulloblastoma. Methods We performed orthogonal CRISPR and CRISPR interference screens in HH-associated medulloblastoma cells treated with pharmacologic inhibitors of CDK6 in vitro, and RNA-sequencing of HH-associated medulloblastomas with genetic deletion of CDK6 in vivo. Mechanistic and functional validation of resistance pathways was performed using CRISPR interference, immunoblotting, immunofluorescence, genetics, and pharmacology. Lipid quantification was carried out by ultra-high performance liquid chromatography-tandem mass spectrometry. Results Our results reveal that decreased ribosomal protein expression underlies resistance to CDK6 inhibition in HH-associated medulloblastoma, leading to endoplasmic reticular (ER) stress and activation of the unfolded protein response (UPR). We show that ER stress and the UPR increase the activity of enzymes producing Smoothened-activating sterol lipids that sustain oncogenic HH signaling in medulloblastoma despite CDK6 inhibition. These discoveries suggest that combination molecular therapy against CDK6 and HSD11ß2, an enzyme producing Smoothened-activating lipids, may be an effective treatment for HH-associated medulloblastoma. In support of this hypothesis, we demonstrate that concurrent genetic deletion or pharmacological inhibition of CDK6 and HSD11ß2 additively blocks the growth of multiple models of HH-associated medulloblastoma in mice. Conclusions Smoothened-activating lipid biosynthesis underlies resistance to CDK6 inhibition in HH-associated medulloblastoma, revealing a novel combination therapy to treat the most common malignant brain tumor in children.
Report on variation in rates of utilization of surgical services in the Commonwealth of Massachusetts
Authors: B. A. Barnes
Journal: JAMA (1985)

This article presents an analysis of over 140,000 selected surgical procedures performed in Massachusetts in 1980, giving the per capita rates of 14 common procedures and of four less frequently performed procedures. The analysis defines 172 geographic areas for the commonly performed procedures and 45 for the less frequently performed procedures. Per capita surgical rates among the defined areas are significantly different from both a statistical and a clinical point of view. Twofold and threefold variations occur frequently across geographic areas. In certain areas, some surgical services appear to be provided at rates substantially different from the statewide rate. We discuss the importance of these data for physicians as well as the implications for the distribution and quality of clinical care and for containment of medical care costs. (<i>JAMA</i>1985;254:371-375)
A Query.
Authors: James W. Baird
Journal: JAMA (1897)

<sub>Fort Yates, N. Dak.</sub>, July 7, 1897. <h3>To the Editor:</h3> —Would you kindly give the formula and method of using Schleich's fluid for anesthesia, and as full particulars as possible of Maragliano's serum, in your next issue? Yours very faithfully, <h3>Answer:</h3> See TheJournal, Dec. 29, 1894, p. 965, for Dr. Würdemann's article on Schleich's method, andThe Journal, Nov. 21, 1896, p. 1105, for an abstract of an article on Maragliano's serum.
Long-term histologic follow-up after orthotopic liver transplantation (OLT) for hepatitis C virus (HCV) infection: Influence of HCV genotype and rejection . Hospital Universitario La Fe, Valencia, SPAIN
Journal: Hepatology (1995)

Limited evidence suggests bariatric surgery can result in high cure rates for obstructive sleep apnea (OSA) in the morbidly obese. We performed a systematic review and meta-analysis to identify the effects of surgical weight loss on the apnea-hypopnea index.Relevant studies were identified by computerized searches of MEDLINE and EMBASE (from inception to March 17, 2008), and review of bibliographies of selected articles. Included studies reported results of polysomnographies performed before and at least 3 months after bariatric surgery. Data abstracted from each article included patient characteristics, sample size who underwent both preoperative and postoperative polysomnograms, types of bariatric surgery performed, results of preoperative and postoperative measures of OSA and body mass index, publication year, country of origin, trial perspective (prospective vs retrospective), and study quality.Twelve studies representing 342 patients were identified. The pooled mean body mass index was reduced by 17.9 kg/m2 (95% confidence interval [CI], 16.5-19.3) from 55.3 kg/m2 (95% CI, 53.5-57.1) to 37.7 kg/m2 (95% CI, 36.6-38.9). The random-effects pooled baseline apnea hypopnea index of 54.7 events/hour (95% CI, 49.0-60.3) was reduced by 38.2 events/hour (95% CI, 31.9-44.4) to a final value of 15.8 events/hour (95% CI, 12.6-19.0).Bariatric surgery significantly reduces the apnea hypopnea index. However, the mean apnea hypopnea index after surgical weight loss was consistent with moderately severe OSA. Our data suggest that patients undergoing bariatric surgery should not expect a cure of OSA after surgical weight loss. These patients will likely need continued treatment for OSA to minimize its complications.
Without Words
Authors: Ersilia M. DeFilippis
Journal: JAMA Cardiology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
The Sign
Authors: Nicky Quinlan
Journal: Annals of Internal Medicine (2014)

Ad Libitum18 February 2014The SignNicky Quinlan, MB, BCh, BAONicky Quinlan, MB, BCh, BAOFrom Stanford, California.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M13-0994 Audio Reading - “The Sign” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "The Sign," by N. Quinlan. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In Timor, a country young and devastated in its leaving,A child's pallid hand against the cool perspiring wall—“Quinlan's sign,” I puff proudly, happy to have a legacyWhere she had none.In the Valley, the doctors don't sweat nor the wallsOn learning a child may die, but dress her up in disease,Run from her for whom we did all that we could,And more.I rejoined the kids kicking ball ... Author, Article, and Disclosure InformationAffiliations: From Stanford, California.Current Author Address: Nicky Quinlan, MB, BCh, BAO; e-mail, [email protected]edu. PreviousarticleNextarticle Advertisement Audio Reading - “The Sign” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "The Sign," by N. Quinlan. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 18 February 2014Volume 160, Issue 4Page: 266KeywordsFeversMemorySweat ePublished: 18 February 2014 Issue Published: 18 February 2014 Copyright & PermissionsCopyright © 2014 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Platinum-based chemotherapy (Pt-chemo) in pancreatic adenocarcinoma (PC) associated with BRCA mutations: A translational case series.
Authors: Ben Tran, Sara Moore, George Zogopoulos, Ayelet Borgida, Spring Holter, Steven Gallinger, Malcolm J. Moore
Journal: Journal of Clinical Oncology (2012)

217 Background: Prognosis of PC is poor and responses to chemotherapy are minimal and short lived. In prior randomized studies, cisplatin and gemcitabine provided no additional benefits over gemcitabine alone. Preclinical data and case reports suggest BRCA cancers have increased sensitivity to Pt-chemo. Our case series characterizes the benefits of Pt-chemo in germline BRCA mutated PC. Methods: Patients with PC and deleterious germline BRCA mutations treated with Pt-chemo were identified using the Ontario Pancreatic Cancer Study and pharmacy databases. Review of clinical records provided demographic, treatment and survival data. Radiology review assessed responses to Pt-chemo. RNA was extracted from tumor samples for gene expression studies using a panel of DNA repair genes and Nanostring technology. BRCA loss of heterozygosity (LOH) was also investigated. Results: We identified 5 PC patients with BRCA mutations (4 BRCA2, 1 BRCA1) who were treated with Pt-chemo: 1 had resectable disease, 1 locally advanced (LA) and 3 metastatic. The resectable patient (T1N0) had 3 cycles of neoadjuvant Pt-chemo, achieving a partial response (PR) and normalization of CA19-9; curative resection and adjuvant Pt-chemo (3 cycles) followed and the patient remains disease free after almost 3 years. The LA patient (T4N0) had 2 cycles of Pt-chemo, achieving a PR and becoming resectable; curative resection and adjuvant Pt-chemo (4 cycles) followed and the patient remains disease free for over 3 years. One metastatic patient remains on Pt-chemo (5 cycles) having achieved a PR and normalization of CA19-9. The other 2 metastatic patients completed 6 and 22 cycles of Pt-chemo, achieving best response of PR and complete response respectively, with progression free survival of 12 and 45 months. Gene expression and LOH results will be presented. Conclusions: Survival and responses to Pt-chemo observed in our case series of BRCA mutant PC adds to existing data supporting the use of Pt-chemo in this subgroup. Although the incidence of BRCA mutations in PC is small, potential survival benefits gained from personalizing treatment using Pt-chemo supports BRCA testing in selected patients.
Anesthesiology
Authors: S. H. Ngai, E. M. Papper
Journal: New England Journal of Medicine (1963)

New Inhalation Anesthetic AgentsThe available anesthetic agents are not ideal. The problems concerned with manufacturing and storage seem to be less acute (at least to the clinicians) than those connected with clinical administration. At present there is no agent that satisfies the criteria set forth by Artusio and Van Poznak.79 80 81 These authors suggested that an ideal anesthetic should be nonflammable, of sufficient potency so that a supplementary agent is not necessary but not potent enough to cause serious circulatory or respiratory depression when used during clinical circumstances. Clinicians make up for the lack of these properties of available anesthetics . . .
Abstract 2949: The impact of drug perturbations on neuroblastoma disease pathways: A pharmaco-transcriptomics approach
Authors: Ramy Elgendy, Elin Almstedt, Michael Vanlandewijck, Sven Nelander
Journal: Cancer Research (2019)

Abstract Neuroblastoma (NB) cells exhibit a complex spectrum of pathway changes associated with oncogene activation, chromosome events, tumor micro-environment and super-enhancer states. So far, elucidating which pharmaceutical compounds could modulate the activation level of each known pathway in NB cells has not been feasible. To solve this problem, we have combined transcriptome profiling of drug-perturbed NB cells with mathematical modeling of public data to create a first map of drug- and NB-specific transcriptional signatures for more than 7000 pharmaceutical compounds. We treated 2 patient-derived xenograft (PDX) NB cell lines with different chemical compounds, at 3 different doses (IC50, IC20, and IC10) and 2 time-points (6 and 24h). The whole-transcriptome of the treated cells was analyzed by a cost-effective hybrid ‘PLATE-Seq/SMART-Seq2’ method. Using factor analysis and supervised machine learning, the data was used to build a model that predicts the NB-specific outcome of 7035 drugs studied in other (non-NB) cell lines in the L1000/LINCS project. Analysis of 768 NB-specific transcriptome profiles, showed that our method accurately detects dose-dependent drug-induced pathway changes in the NB cells, including alteration of characteristic pathways and risk signatures. From the 768 profiles, our best-fitted machine learning model was then extended to 7035 compounds by in silico extrapolation, providing a first panel of estimated drug effects in NB cells. Our constructed NB pharmacological map provides a detailed view of both predicted and in vitro-validated drug-NB interactions. Effective treatments for high-risk NB are currently lacking. Using a new and cost-effective strategy, we could build an accurate map of drug-induced pathway alterations, for network pharmacology and drug repositioning for NB patients. Citation Format: Ramy Elgendy, Elin Almstedt, Michael Vanlandewijck, Sven Nelander. The impact of drug perturbations on neuroblastoma disease pathways: A pharmaco-transcriptomics approach [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2949.
Bone Sarcomas Following Radiation Therapy
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Section IV. Assessment of the BCDDP'S Experience for the Measurement of Benefit from Screening
Journal: JNCI Journal of the National Cancer Institute (1979)

Section IV. Assessment of the BCDDP'S Experience for the Measurement of Benefit from Screening Get access JNCI: Journal of the National Cancer Institute, Volume 62, Issue 3, March 1979, Pages 685–690, https://doi.org/10.1093/jnci/62.3.685 Published: 01 March 1979
THE NATURE OF CYSTINURIA
Journal: JAMA (1930)

Although the anomaly of metabolism known as cystinuria has long been recognized, one cannot study the literature of this "chemical malformation" without encountering persistent and confusing contradictions. Most conspicuous, perhaps, are the occasional discrepancies between the urinary output of neutral sulphur assumed to be a measure of the unoxidized cystine passed through the kidneys and the actual amounts of cystine that can be separated in crystalline form. The differences in the readiness with which the precipitation of cystine from cystinuric urine seems to take place in different cases have been ascribed to variations in the solubility of the amino-acid in mediums of unlike hydrogen ion concentration. Perhaps the most confusing facts have been the observations, repeatedly verified, that certain patients with cystinuria oxidize free cystine administered to them about as freely as a normal person does; yet they eliminate cystine when protein is fed. On a standard diet, such patients
Dr. W. S. Tegner
Journal: British Journal of Sports Medicine (1972)

came in under the cliff.What luck a fresh frozen lead along the edge!There was an easy ramp off the shelf ice now it was fast flat sea.I dug in the ski sticks and away shot the skis.How effortless.We could easily do twenty miles on this.On the sea I worried about bears.We had no gun.They could be lurking behind floes but fortunately none appeared.Not even a footprint.Ahead was Cape Aldrich.The sun was lost behind the hills.It was after midnight.I began to feel cold, tired and hungry.We traversed on some sloping snow -the skis wanted to run down.It was difficult holding on.